Chemotherapy Induced Neutropenia - Pipeline Review, H2 2012

Publisher Name :
Date: 26-Dec-2012
No. of pages: 87
Inquire Before Buying

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Chemotherapy Induced Neutropenia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia. Chemotherapy Induced Neutropenia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Induced Neutropenia.
- A review of the Chemotherapy Induced Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chemotherapy Induced Neutropenia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Chemotherapy Induced Neutropenia 10
Chemotherapy Induced Neutropenia Therapeutics under Development by Companies 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Chemotherapy Induced Neutropenia Therapeutics - Products under Development by Companies 19
Companies Involved in Chemotherapy Induced Neutropenia Therapeutics Development 21
Kyowa Hakko Kirin Co., Ltd. 21
Dong-A Pharmaceutical Co., Ltd. 22
Maxygen, Inc. 23
Teva Pharmaceutical Industries Limited 24
Sandoz Inc. 25
Zosano Pharma, Inc. 26
LTT Bio-Pharma Co., Ltd. 27
Cellerant Therapeutics, Inc. 28
Med Discovery SA 29
Synageva BioPharma Corp. 30
Phage Biotechnology Corporation 31
Inimex Pharmaceuticals, Inc. 32
Bolder Biotechnology, Inc. 33
Welichem Biotech Inc. 34
USV Limited. 35
Pfenex Inc. 36
Eurofarma 37
Chemotherapy Induced Neutropenia - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
MAXY-G34 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MDPK-67b - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Slow-Release G-CSF - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Pegylted GCSF - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
filgrastim - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
balugrastim - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IMX-942 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CLT-008 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
filgrastim - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
pegfilgrastim - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pegfilgrastim - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
lipegfilgrastim - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
WBI-2100 + [cisplatin] - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
WBI-2100 + [gemcitabine hydrochloride] - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
WBI-2100 + [dacarbazine] - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
WBI-2100 + [paclitaxel] - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
TXA127 + Erythropoietin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
filgrastim - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BBT-015 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BBT-018 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IRX-4310 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
pegfilgrastim - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
filgrastim - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
filgrastim - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
filgrastim - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
F-627 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
F-627 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
filgrastim Biosimilar - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pegfilgrastim Biosimilar - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Chemotherapy Induced Neutropenia Therapeutics - Drug Profile Updates 75
Chemotherapy Induced Neutropenia Therapeutics - Discontinued Products 79
Chemotherapy Induced Neutropenia Therapeutics - Dormant Products 80
Chemotherapy Induced Neutropenia - Product Development Milestones 81
Featured News & Press Releases 81
Jun 29, 2012: Teva Pharma Provides Clinical Update On Balugrastim At MASCC/ISOO 2012 International Symposium On Supportive Care In Cancer 81
Jun 29, 2012: Teva Pharma Provides Clinical Update On Lipegfilgrastim At MASCC/ISOO 2012 International Symposium On Supportive Care In Cancer 81
Oct 10, 2011: Maxygen Announces Final Rejection Of All Claims Of Amgen ?804 Patent In Inter Partes Reexamination Proceeding 82
May 31, 2011: Teva Announces Data On Granulocyte Colony Stimulating Factor Compounds For Prevention Of Chemotherapy-Induced Neutropenia In Breast Cancer Patients 82
May 31, 2011: Teva To Present Phase II Data Of Granulocyte Colony Stimulating Factor XM22 At ASCO 82
Mar 24, 2011: Telik Announces Preclinical Presentation At 102nd Annual Meeting Of American Association For Cancer Research 83
Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients 83
Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants 84
Dec 01, 2009: Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia 84
May 08, 2002: Amgen to Acquire Filgrastim and Pegfilgrastim in Europe from Roche 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products Under Development for Chemotherapy Induced Neutropenia, H2 2012 10
Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Development by Companies, H2 2012 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Development by Companies, H2 2012 (Contd..1) 20
Kyowa Hakko Kirin Co., Ltd., H2 2012 21
Dong-A Pharmaceutical Co., Ltd., H2 2012 22
Maxygen, Inc., H2 2012 23
Teva Pharmaceutical Industries Limited, H2 2012 24
Sandoz Inc., H2 2012 25
Zosano Pharma, Inc., H2 2012 26
LTT Bio-Pharma Co., Ltd., H2 2012 27
Cellerant Therapeutics, Inc., H2 2012 28
Med Discovery SA, H2 2012 29
Synageva BioPharma Corp., H2 2012 30
Phage Biotechnology Corporation, H2 2012 31
Inimex Pharmaceuticals, Inc., H2 2012 32
Bolder Biotechnology, Inc., H2 2012 33
Welichem Biotech Inc., H2 2012 34
USV Limited., H2 2012 35
Pfenex Inc., H2 2012 36
Eurofarma, H2 2012 37
Assessment by Monotherapy Products, H2 2012 38
Assessment by Combination Products, H2 2012 39
Assessment by Stage and Route of Administration, H2 2012 41
Assessment by Stage and Molecule Type, H2 2012 43
Chemotherapy Induced Neutropenia Therapeutics - Drug Profile Updates 75
Chemotherapy Induced Neutropenia Therapeutics - Discontinued Products 79
Chemotherapy Induced Neutropenia Therapeutics - Dormant Products 80

List of Figures
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2012 10
Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 38
Assessment by Combination Products, H2 2012 39
Assessment by Route of Administration, H2 2012 40
Assessment by Stage and Route of Administration, H2 2012 41
Assessment by Molecule Type, H2 2012 42
Assessment by Stage and Molecule Type, H2 2012 43

  • Overview of Global and Chinese 3D Printing Market 2015-2020
    ‘2015 3D Printing Industry Report -Global and Chinese Market’ is a comprehensive research report that describes the scope of the Global and Chinese 3D printing industry, analyzing the end-users behavior and the latest industry trends. Also, the report evaluates the growth prospects and the up-coming opportunities in the industry over the forecast period of 2015-2020. [...]
  • Schottky Diode Industry Research – 2015 Global and Chinese Market Overview
    ‘2015 Schottky Diode Industry Report – Global and Chinese Market Scenario’ is a top-notch research report, delivering premium industry insights and explanations of complex business scenarios. The report systematically articulates various growth prospects and current market challenges being faced by the existing industry players. The research report also drafts a meticulous business forecast that provides [...]
  • Codeine (CAS 76-57-3) Industry Research Report – 2009-2019 Market Forecast
    ‘Global and Chinese Codeine (CAS 76-57-3) Industry, 2009-2019 Market Research Report’, a systematically structured research report, that aims to deliver a detailed understanding of vivid market scenarios prevalent in the Codeine (CAS 76-57-3) industry to the user.  The report articulates various sections that thoroughly describe all key-aspects of the Codeine (CAS 76-57-3) industry. The report [...]
  • Global and Chinese Mainframe Banking Industry 2015 Outlook
    2015 Banks Mainframe Industry Report -Global and Chinese Market is a detailed market research report, delivering premium industry insights and analyzing the growth prospects of the industry over the forecast period of 2015-2020. The systematically structured sections of the research report, aims at conveying a strong business understanding to the user, enhancing the decision making [...]
  • Global and Chinese Market Situation of Milk Infant Formula Industry Over the Period of 2009-2019
    ‘Market Research Report on Global and Chinese Milk Infant Formula Industry, 2009-2019’ a comprehensive market study, that analyses various market landscape and key-aspects of the industry, delivering premium business insight and thorough understanding of the Global and Chinese market conditions to the user. Industry experts have methodologically structured the elaborative sections of the research report, [...]
    • The Oil Drilling Rig Industry
    • The Oil Drilling Rig Industry is characterized with a few typical work specific to this industry only. The work begins with the search for new oil basins or construction of wells. During this time the services of drilling contractors and se…

    • HER2-Negative Breast Cancer’s Therapeutic Market
    • HER2-Negative Breast Cancer is the most common form of cancer occurring in women. The long term survival of patients diagnosed with HER2-Negative Breast Cancer depends solely on its early detection as till now there is no medicine that can …

    • The Market of Plate Heat Exchanger
    • Plate heat exchanger is not only very useful but its also easy to maintain, its compact design makes it more efficient, the product is highly cost-efficient and also the materials of this product are easily available. There are some limitat…

    • The Industry of Binding Machines
    • Binding of books and papers is one of the most important aspect of buying and selling books and thus the demand of binding machines. There are different kinds of binding machines available in the market. The binding type determines the bind…

    • The Boom In Women Infertility Market
    • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Oncology Therapeutics Market to 2017 - High Unmet Need in Management and Treatment of Metastatic Cancers to Drive Drug Development
    Published: 31-Dec-2011        Price: US 3500 Onwards        Pages: 0
    Report Summary GBI Research, the leading business intelligence provider, has released its latest research, "Oncology Therapeutics Market to 2017 - High Unmet Need in Management and Treatment of Metastatic Cancers to Drive Drug Development", which provides insights into the global oncology therapeutics market and market forecasts until 2017. The report provides an in-depth analysis of major oncology indications, which includes breast cancer, colorectal cancer, Non-Hodgkin's lymphoma (NHL), Non-S......
  • Liver Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
    Published: 01-Jan-2012        Price: US 6995 Onwards        Pages: 0
    GlobalData, the industry analysis specialist, has released its new report, “Liver Cancer - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global Liver Cancer market. The report provides comprehensive information on Liver Cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global Liver Cancer market. It analyses the treatment usage patterns in the global Liver ......
  • Bile Duct Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018
    Published: 30-Jan-2012        Price: US 3995 Onwards        Pages: 0
    GlobalData, the industry analysis specialist, has released its new report, "Bile Duct Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Bile Duct Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Bile Duct Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significan......
  • Hematological Cancer Therapies: Pipelines, Markets, and Business Considerations
    Published: 29-Feb-2012        Price: US 2495 Onwards        Pages: 215
    In recent years, newer and more specific therapies for hematological cancers have been developed, such as targeted small-molecule drugs and biological therapies including monoclonal antibodies. However, there remains significant need from a clinical perspective, as well as challenges and opportunities for pharmaceutical companies. This report discusses: The different types of hematological cancers, including information about the specific disease, its epidemiology, subtypes and/or st......
  • Game Changers in Breast Cancer Therapies
    Published: 09-May-2012        Price: US 3400 Onwards        Pages: 175
    Breast cancer therapies are entering a new era as game-changers emerge for each of the major breast cancer patient populations. New market entrants must possess drug profiles and a savvy clinical development program to overcome such barriers to entry as a stringent regulatory environment and the incursion of cost containment within oncology. This TriMark Publications report provides comprehensive information on major and minor shapers of the breast cancer drug treatment landscape. The study incl......
  • 2012 World Cancer Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country
    Published: 20-Jun-2012        Price: US 1950 Onwards        Pages: 11
    This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, estimates of the number of laboratories performing cancer tests, as well as ten-year test volume and sales forecasts by country. Contains 11 pages and 3 tables......
  • Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019
    Published: 30-Jun-2012        Price: US 3995 Onwards        Pages: 70
    GlobalData, the industry analysis specialist, has released its new report, “Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Laryngeal Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Laryngeal Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significant......
  • Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline
    Published: 10-Jul-2012        Price: US 3500 Onwards        Pages: 172
    Summary GBI Research, the leading business intelligence provider, has released its latest research, “Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline” which provides insights into the global oncology pipeline. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. The report pro......
  • Prostate Cancer - Pipeline Review, H2 2012
    Published: 31-Aug-2012        Price: US 2500 Onwards        Pages: 498
    Global Markets Direct’s, ''Prostate Cancer - Pipeline Review, H2 2012'', provides an overview of the Prostate Cancer therapeutic pipeline. This report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Prostate Cancer. ''Prostate Cancer - Pipeline Review, H2 2012'' is built using data and information sourced from......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs